Cathepsin O (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-CathepsinO
In stock
- SKU
- REC-CathepsinO
Target Overview
Cathepsin O (CTSO; UniProt P43234) is a lysosomal cysteine protease of the papain superfamily encoded by the CTSO gene. The full-length human precursor spans 321 amino acids and undergoes propeptide processing to yield the mature, catalytically active enzyme. This recombinant form is produced in HEK293 mammalian cells, a system that supports the glycosylation patterns and folding environment characteristic of the native lysosomal enzyme — important considerations when generating material for inhibitor binding studies or conformation-sensitive antibody validation. Researchers use this recombinant in fluorogenic peptide-substrate cleavage assays to measure baseline proteolytic activity and to determine inhibitor potency (IC50) under defined pH conditions approximating the lysosomal environment. Because HEK293-expressed material retains post-translational modifications present in human tissue sources, it also serves as a well-defined positive control antigen in Western blot and immunohistochemistry validation workflows. The recombinant is validated for reactivity against human CTSO, with potential cross-reactivity predicted for mouse, rat, pan, and monkey orthologues based on sequence conservation — researchers should confirm orthologous activity experimentally for non-human applications. For antibody-based experiments, this recombinant pairs directly with Triple Point Biologics' matched Cathepsin O antibody (SKU: RP-CathepsinO), providing a defined antigen source for specificity confirmation, dot-blot titration, and immunodepletion controls. The combination of recombinant protein and matched antibody in a single-vendor workflow reduces a common source of lot-to-lot variability in antibody validation experiments.
Background
Applications
- Fluorogenic peptide-substrate cleavage assay to measure Cathepsin O proteolytic activity under lysosomal pH conditions
- Inhibitor IC50 determination in small-molecule screening campaigns targeting cysteine proteases
- Positive control antigen for Western blot validation of anti-CTSO antibodies, paired with RP-CathepsinO
- Dot-blot titration to establish antibody sensitivity and linearity for anti-CTSO immunodetection
- Recombinant standard for absolute quantification of CTSO in proteomics and mass spectrometry workflows
- Functional characterisation of CTSO missense variants identified in genetic studies of vascular or metabolic disease
- Immunodepletion control to confirm antibody specificity in IHC or immunofluorescence experiments
References
- Fréneau M et al. Identification of rare missense variants reducing cathepsin O secretion in families with intracranial aneurysm. Cardiovasc Res. 2026. doi:10.1093/cvr/cvaf279. PMID: 41508845
- Zhang C et al. Novel treatment strategies for cardiovascular and pulmonary diseases: Insights from cathepsin-related Mendelian randomization and Bayesian colocalization. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000046963. PMID: 41496066
- Tan L et al. Causal roles of cathepsins family members in breast cancer subtypes: insights from Mendelian randomization and bioinformatics analysis. Discov Oncol. 2025. doi:10.1007/s12672-025-03787-3. PMID: 41123761
- Yue H et al. Identification of Potential Therapeutic Targets for Sepsis Using Mendelian Randomization and Integrated eQTL/pQTL Analysis. Int J Gen Med. 2025. doi:10.2147/IJGM.S535716. PMID: 41089542
- Giraudi PJ et al. Serum proteome signatures associated with liver steatosis in adolescents with obesity. J Endocrinol Invest. 2025. doi:10.1007/s40618-024-02419-x. PMID: 39017916
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Lysosome |
Frequently Asked Questions
What molecular weight does recombinant Cathepsin O run at on SDS-PAGE or Western blot?
The full-length human CTSO precursor (UniProt P43234) is 321 amino acids with a predicted unprocessed MW of ~37 kDa. On reducing SDS-PAGE, the HEK293-expressed recombinant typically migrates at approximately 38–42 kDa due to N-linked glycosylation added by the mammalian expression system. Under denaturing WB conditions you may observe a diffuse or doublet band in this range reflecting glycoform heterogeneity. If you need a sharp, defined band for ladder calibration, treat the sample with PNGase F prior to electrophoresis to collapse glycoforms to the ~37 kDa core.
What processing form is this recombinant Cathepsin O — full-length precursor or mature active enzyme?
This recombinant is produced as the mature, catalytically active form following propeptide removal. HEK293 cells support the autocatalytic or trans-processing that cleaves the N-terminal propeptide (roughly residues 1–113 of the precursor), yielding the active enzyme domain. You should not expect a propeptide band in reducing SDS-PAGE. If your experimental model involves tracking propeptide processing as a readout, you would need to separately express the zymogen form — this product is not appropriate for that application.
What substrates does Cathepsin O cleave, and which fluorogenic peptide should I use in an activity assay?
Cathepsin O is a cysteine protease with a preference for substrates bearing hydrophobic residues at the P2 position, similar to other papain-family cathepsins. The fluorogenic substrate Z-Phe-Arg-AMC (carbobenzoxy-Phe-Arg-7-amino-4-methylcoumarin) is a well-established choice for initial activity confirmation at 1–10 µM substrate concentration. Release of AMC is monitored by excitation at 380 nm / emission at 460 nm. Cathepsin L also cleaves this substrate, so include a cathepsin-selective inhibitor (e.g., E-64 at 10 µM as a negative control) to confirm cysteine-protease-dependent signal.
What buffer conditions should I use for a Cathepsin O activity assay to approximate lysosomal pH?
For activity assays, use 50 mM sodium acetate, 1 mM EDTA, 2–5 mM DTT, pH 5.5. Pre-activate the enzyme by incubating in assay buffer with DTT for 10–15 minutes at 37°C before adding substrate — cysteine proteases require a reducing environment to maintain the active-site thiol in its reduced state. The storage buffer supplied (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) maintains stability at -20°C but is not optimal for catalytic activity; dilute into pH 5.5 acetate buffer immediately before use. Avoid DMSO above 1% (v/v) in inhibitor dilutions.
What starting concentration of recombinant Cathepsin O should I use for an IC50 inhibitor assay?
A starting point of 5–20 nM recombinant Cathepsin O in the assay well is typical for IC50 determinations, keeping enzyme concentration well below the Ki of your inhibitor to avoid stoichiometric-binding artifacts. Use Z-Phe-Arg-AMC at a concentration bracketing the Km (empirically determined, but 10 µM is a reasonable starting estimate). Run an enzyme titration curve first to identify the linear range of AMC release over your assay window (30–60 min at 37°C, pH 5.5). For tight-binding inhibitors, drop enzyme to 1–2 nM and use Morrison's tight-binding IC50 equation.
Can I use Cathepsin O (Recombinant) as a positive control antigen for Western blot with the matched TPB antibody?
Yes — this recombinant is the recommended positive control for use with RP-CathepsinO (Triple Point Biologics rabbit polyclonal anti-Cathepsin O antibody; see /anti-cathepsin-o-rabbit-polyclonal-antibody). Both were developed in the same lab from the same antigen, so epitope compatibility is confirmed rather than predicted. Load 20–50 ng of recombinant Cathepsin O per lane alongside your cell lysate samples. The antibody is validated for Western blot, so you should see a clean band in the 38–42 kDa region. This is particularly useful when working with cell lines expressing low endogenous CTSO.
How much recombinant Cathepsin O should I load as a Western blot positive control to get a clean band?
Load 25–50 ng per lane as a starting point when using RP-CathepsinO at a 1:1,000–1:2,000 primary antibody dilution. This gives a clearly visible band without overwhelming the lane or cross-contaminating adjacent sample wells by diffusion. If you are optimizing antibody concentration, run a 2-fold dilution series of the recombinant (10, 25, 50, 100 ng) in parallel. Because HEK293-expressed material retains native glycosylation, the band position will closely match endogenous CTSO from human tissue or cell lysate, making it a reliable size reference as well as a signal control.
How should I store and handle recombinant Cathepsin O to preserve activity, and what is the shelf life?
Recombinant Cathepsin O is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and shipped on dry ice. Upon receipt, aliquot immediately into single-use volumes and store at -20°C; avoid repeated freeze-thaw cycles, which progressively denature cysteine proteases. Under these conditions, activity is stable for at least 12 months from the date of manufacture (see CoA for lot-specific expiry). Do not dilute the stock into water or low-salt buffers for long-term storage — the glycerol and salt are critical cryoprotectants. Prepare working dilutions in pH 5.5 acetate assay buffer immediately before each experiment.
Validation imagery coming soon
Western blot validation figures for REC-CathepsinO will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.